Following recent research demonstrating that ipilimumab and vemurafenib both improve overall survival in melanoma, the panel outline how they feel these two drugs should be incorporated into clinical practice and future clinical trials. When deciding what treatment is most appropriate clinicians must consider factors such as tumour burden, presence of BRAF mutations and speed of progression. The panel conclude by stressing that although massive advances have been made in developing melanoma therapies, the majority of patients will still die from their disease and there is still a lot of work to be done developing treatments before melanoma can be seen as a chronic disease.